Sensei Bio enters consulting agreement with former CFO Erin Colgan for transition through April 30, 2024

Sensei Biotherapeutics, Inc.

Erin Colgan, former CFO, will provide transition services through April 30, 2024 under a consulting agreement.
Consulting fee of $1,640 per business day.
Exercise period for her existing vested stock options extended to October 7, 2024 or later per plan/award.
Agreement expires automatically on April 30, 2024 unless terminated earlier.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Erin Colgan

Chief Financial Officer

SNSE · Sensei Biotherapeutics, Inc.

Filed: April 12, 2024, 7:59 PM ET

On April 11, 2024, Sensei Biotherapeutics, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Erin Colgan, the Company’s former Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erin Colgan departed as Chief Financial Officer at Sensei Biotherapeutics, Inc..

Action: departed
Role: Chief Financial Officer

Exact text from the filing

On April 11, 2024, Sensei Biotherapeutics, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Erin Colgan, the Company’s former Chief Financial Officer.

View on SEC.gov

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-094756

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.